Results 131 to 140 of about 2,415,366 (239)

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1368-1378, November 2026.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Early Administration of Rifampicin Does Not Induce Increased Resistance in Septic Two-Stage Revision Knee and Hip Arthroplasty

Antibiotics
Background/Objectives: Periprosthetic joint infection (PJI) is a severe complication that follows arthroplasty and occurs in approximately 2% of all cases. One of several cornerstones of therapy is an optimized antibiotic regimen. Early administration of
Leonard Grünwald, Benedikt Paul Blersch, Bernd Fink   +2 more
doaj   +1 more source

Sputum culture and phenotypic drug resistance of 243 Xpert rifampicin-resistant TB patients.

, 2019
Sputum culture and phenotypic drug resistance of 243 Xpert rifampicin-resistant TB patients.
Reinout van Crevel (60606), Bony Wiem Lestari (6411809), Prayudi Santoso (6411812), Arto Yuwono Soeroto (6411806), Bachti Alisjahbana (270243), Basti Andriyoko (6411815), Philip C. Hill (20648), Lidya Chaidir (103945)   +7 more
core   +1 more source

Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs [PDF]

, 2013
Includes abstract.Includes bibliographical references.The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in 78 patients with tuberculosis were described using non-linear mixed effects modeling.
Chigutsa, Emmanuel
core   +1 more source

Tuberculosis prevalence and rifampicin resistance among presumptive patients in Nasarawa State: A three-year retrospective study

One Health Bulletin
Objective: To investigate the prevalence and rifampicin resistance of tuberculosis among presumptive patients in Nasarawa state, Nigeria. Methods: Patient data collected from January 2019 to December 2021 were retrospectively computed from the register ...
Ibrahim Hassan Ikrama, Amadou Talfi Zakou, Ngolo Jebes Lamini, Celestine Osanga, Attari Nasara Dogara, Lambo Yamusa Wakili, Daniel Abah Augustine, Muhammad Maryam Hassan, Regina Aluku, Caleb Luka Kyari, Agbawu M Agbawu, Godwin Attah Obande, Aleruchi Chuku   +12 more
doaj   +1 more source

Inhaled Nanomedicines for Lung Diseases and Injuries: Pharmacological Advances and Clinical Translation

MedComm, Volume 7, Issue 11, November 2026.
Graphical overview of bioinspired regenerative platforms designed to remodel the diseased lung microenvironment. These systems integrate gene addition, siRNA‐mediated transcript silencing, CRISPR‐based modulation, and base editing approaches to promote alveolar repair, AT2‐to‐AT1 regeneration, resolution of inflammation, and restoration of vascular ...
Kajal Kamra, Sonal Gaur, Jaswinder Singh
wiley   +1 more source

Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia

, 2017
Kefyalew N Jaleta,1,* Mucheye Gizachew,1 Baye Gelaw,1 Habtie Tesfa,2 Alem Getaneh,1 Belete Biadgo3,* 1Department of Medical Microbiology, 2Department of Medical Parasitology, 3Department of Clinical Chemistry, School of Biomedical and Laboratory Sciences,
Getaneh A, Jaleta KN, Gelaw B, Biadgo B, Gizachew M, Tesfa H   +5 more
core  

Drug–Drug Interactions of Cenobamate With Medications: Dose‐Dependent Induction/Inhibition and Clinical Implications

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Cenobamate causes dose‐dependent cytochrome P450 (CYP)2B6 and CYP3A4 induction and CYP2C19 inhibition, raising concern over multi‐pathway drug–drug interactions (DDIs) in patients with epilepsy treated with cardiovascular co‐medications. We developed a physiologically based pharmacokinetic (PBPK) model for cenobamate and verified it using ...
Hiroyuki Ichida, Takaharu Nakao, Takanori Mori, Reina Makino, Marika Nakagawa, Kazuhiro Yoneda, Yoshiyuki Yamaura, Masanori Kuribayashi   +7 more
wiley   +1 more source

The Blind Spot of GeneXpert MTB/RIF: Isoniazid‐Resistant, Rifampicin‐Susceptible Tuberculosis Detected on Phenotypic Drug Susceptibility Testing

Respirology Case Reports, Volume 14, Issue 11, November 2026.
GeneXpert MTB/RIF reports only rifampicin resistance, so a result of ‘rifampicin resistance not detected’ does not exclude isoniazid resistance. In this young man with hemoptysis and bilateral infiltrates, phenotypic drug susceptibility testing of bronchoalveolar lavage revealed isoniazid‐resistant, rifampicin‐susceptible tuberculosis after 1 month of ...
Hafiz Muhammad Faisal Nadeem, Ali Gohar, Muhammad Faisal Jakhar, Rabbia Abbas, Taqdees Noor, Muhammad Husnain Ahmad   +5 more
wiley   +1 more source